Literature DB >> 31042569

Sex differences in the expression of morphine withdrawal symptoms and associated activity in the tail of the ventral tegmental area.

Samara A M Bobzean1, Saurabh S Kokane1, Brandon D Butler1, Linda I Perrotti2.   

Abstract

Recent studies, in male rodents, have begun to elucidate a role for the GABAergic neurons in the tail of the ventral tegmental area (tVTA) in morphine withdrawal. To date, the mechanisms underlying morphine withdrawal have been studied almost exclusively in male animals. As a result, there is a considerable gap in our current understanding of the processes underlying sex differences in morphine withdrawal behaviors and its effects on cellular activity in the tVTA in females. The purpose of the present study was to investigate the influence of sex on the expression and duration of spontaneous somatic morphine withdrawal syndrome, and to characterize the relationship between spontaneous somatic withdrawal symptoms and cellular activation (measured as phosphorylated CREB; pCREB), in the GABAergic tVTA in male and female rats. Morphine-dependent adult male and female Long Evans rats underwent 72 h of spontaneous withdrawal, and somatic withdrawal symptoms were assessed every 12 h. Male morphine-dependent rats expressed more severe symptoms during the early phases of withdrawal compared to females. Although, females demonstrated lower overall symptom severity, their symptoms persisted for a longer period of time, thus demonstrating higher withdrawal-symptom severity than males during late withdrawal. pCREB activity in the tVTA was elevated in morphine-withdrawn rats and was positively correlated with the severity of withdrawal symptoms. These results demonstrate sex differences in the timing of the expression of somatic withdrawal. Our data add to the growing body of evidence demonstrating a role for the tVTA in morphine withdrawal and begin to establish a sex-dependent behavioral and molecular profile within this brain region.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CREB; Dependence; Opioid; RMTg; Somatic withdrawal; Spontaneous withdrawal; Time-course

Year:  2019        PMID: 31042569      PMCID: PMC6662583          DOI: 10.1016/j.neulet.2019.04.057

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  6 in total

1.  Morphine reduces the interest for natural rewards.

Authors:  Alessandro Piccin; Gilles Courtand; Angelo Contarino
Journal:  Psychopharmacology (Berl)       Date:  2022-04-08       Impact factor: 4.415

2.  Use of home cage wheel running to assess the behavioural effects of administering a mu/delta opioid receptor heterodimer antagonist for spontaneous morphine withdrawal in the rat.

Authors:  Michael M Morgan; Danielle L Peecher; John M Streicher
Journal:  Behav Brain Res       Date:  2020-10-06       Impact factor: 3.332

3.  Divergent profiles of fentanyl withdrawal and associated pain in mice and rats.

Authors:  Olivia Uddin; Carleigh Jenne; Megan E Fox; Keiko Arakawa; Asaf Keller; Nathan Cramer
Journal:  Pharmacol Biochem Behav       Date:  2020-12-11       Impact factor: 3.533

4.  Sexually dimorphic neuroimmune response to chronic opioid treatment and withdrawal.

Authors:  Mohit Kumar; Jennifer R Rainville; Kori Williams; Joshua A Lile; Georgia E Hodes; Fair M Vassoler; Jill R Turner
Journal:  Neuropharmacology       Date:  2021-01-22       Impact factor: 5.250

5.  Bulleyaconitine A Inhibits Morphine-Induced Withdrawal Symptoms, Conditioned Place Preference, and Locomotor Sensitization Via Microglial Dynorphin A Expression.

Authors:  Meng-Jing Zhao; Mi-Ya Wang; Le Ma; Khalil Ali Ahmad; Yong-Xiang Wang
Journal:  Front Pharmacol       Date:  2021-02-26       Impact factor: 5.810

6.  Sex- and Dose-Dependent Differences in the Development of an Addiction-Like Phenotype Following Extended-Access Fentanyl Self-Administration.

Authors:  Eleanor Blair Towers; Ben Setaro; Wendy J Lynch
Journal:  Front Pharmacol       Date:  2022-03-17       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.